Trial Profile
Phase II proof-of-concept trial of SUVN 502 in patients with cognitive dysfunction.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 19 May 2011
Price :
$35
*
At a glance
- Drugs Masupirdine (Primary)
- Indications Alzheimer's disease; Attention-deficit hyperactivity disorder; Cognition disorders; Parkinson's disease; Schizophrenia
- Focus Therapeutic Use
- Sponsors Suven Life Sciences
- 19 May 2011 Planned initiation date changed from 1 Sep 2009 to 1 Dec 2011.
- 03 Aug 2009 New trial record.